Review



normal human dermal fibroblast  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC normal human dermal fibroblast
    Normal Human Dermal Fibroblast, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2001 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Dermal+Fibroblast%3B+Normal%2C+Human%2C+Adult/pmc13755844-329-37-42
    Average 99 stars, based on 2001 article reviews
    normal human dermal fibroblast - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Interferon-gamma, bacterial lipopolysaccharide, and tumor necrosis factor-alpha induce CD11a mRNA and protein via Na+/H+ exchange and protein kinase C-dependent mechanisms in tissue macrophages.
    Article Snippet: ( o 0 Previously CD11a or leukocyte function-associated ntigen a-1 was found to be induced at the surface rotein level in thioglycolate-elicited peritoneal acrophages by bacterial lipopolysaccharide and nterferon-g. To investigate this induction further, orthern blotting and enzyme-linked immunosorbent ssays were used to examine the role of second mesengers in CD11a gene product induction by these gents.. Here I report that CD11a RNA and cell surface rotein induced by bacterial lipopolysaccharide and umor necrosis factor-a are sensitive to inhibition of rotein kinase C, while insensitive to inhibition of a/H exchange.. CD11a induction by interferon-g onversely is sensitive to inhibition of Na/H exhange and insensitive to inhibition of protein kinase .

    Derivative Assay:

    Article Title: Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer.
    Article Snippet: Phenotypic expression of human leukocyte antigen (HLA)-E on the surface of tumor lesions includes intact heterodimer [HLA-E heavy chain and b2-microglobulin (b2m)] and b2m-free monomer.. Anti-HLA-E monoclonal antibodies (mAbs), MEM-E=02 or 3D12 bind to the peptide sequences in b2m-free HLA-E, which is common and shared with HLA-Ia monomers.. A newly developed monospecific anti-HLA-E mAb (TFL-033) recognizes HLA-E-restricted peptide sequences on a1 and a2 helices away from b2-m-site.



    Similar Products

    99
    ATCC normal human dermal fibroblast
    Normal Human Dermal Fibroblast, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Dermal+Fibroblast%3B+Normal%2C+Human%2C+Adult/pmc13755844-329-37-42
    Average 99 stars, based on 1 article reviews
    normal human dermal fibroblast - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    90
    DePuy Synthes the cemented attune™ primary knee system®
    The Cemented Attune™ Primary Knee System®, supplied by DePuy Synthes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/attune+knee+system/nct06074744-6-10-14
    Average 90 stars, based on 1 article reviews
    the cemented attune™ primary knee system® - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    ATCC human umbilical vein endothelial cells huvecs
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Human Umbilical Vein Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pmc13771586-157-6-15
    Average 99 stars, based on 1 article reviews
    human umbilical vein endothelial cells huvecs - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology ahr primary antibody
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Ahr Primary Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/AHR+Rabbit+pAb/pmc13771667-390-29-34
    Average 94 stars, based on 1 article reviews
    ahr primary antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    ATCC human peripheral blood mononuclear cells
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Human Peripheral Blood Mononuclear Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Peripheral+Blood+Mononuclear+Cells+(PBMC)%2C+Normal%2C+Human/pmc13770899-72-7-14
    Average 99 stars, based on 1 article reviews
    human peripheral blood mononuclear cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    93
    Proteintech primary antibodies fstl1
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Primary Antibodies Fstl1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/FSTL1+Antibody/pm43000092-69-3-8
    Average 93 stars, based on 1 article reviews
    primary antibodies fstl1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    97
    ATCC human epithelial cell line
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Human Epithelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Small+Airway+Epithelial+Cells%3B+Normal%2C+Human/pm43027366-93-4-18
    Average 97 stars, based on 1 article reviews
    human epithelial cell line - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    95
    ABclonal Biotechnology primary rabbit polyclonal anti lc3a lc3b antibody
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Primary Rabbit Polyclonal Anti Lc3a Lc3b Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/LC3A%2FLC3B+Rabbit+pAb/pmc13760597-68-0-5
    Average 95 stars, based on 1 article reviews
    primary rabbit polyclonal anti lc3a lc3b antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    99
    ATCC pbmc derived cd14 monocytes
    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein <t>endothelial</t> cells <t>(HUVECs).</t>
    Pbmc Derived Cd14 Monocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/Primary+Peripheral+Blood+CD14%2B+Monocytes%2C+Normal%2C+Human/pmc13763876-254-9-13
    Average 99 stars, based on 1 article reviews
    pbmc derived cd14 monocytes - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    Proteintech rabbit anti human atgl primary antibody
    RBP1 silencing induces <t>ATGL-dependent</t> lipid mobilization. A Representative immunoblot of LC3 protein levels in control and siRBP1 LECs (n = 3). Densitometric quantification of protein levels (normalized to GAPDH as loading control and expressed relative to the control condition) is shown beneath the blot. B , C Representative images of <t>BODIPY-palmitate</t> 493/503 (green) staining ( B ) and quantification of lipid droplet density per cell ( C ) in control and siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). D Representative immunoblot of ATG5 protein levels in siRBP1 versus control LECs following treatment with chloroquine (CQ) (n = 3). Densitometric quantification of protein levels (normalized to vinculin as loading control and expressed relative to the control condition) is shown beneath the blot. E LC–MS measurements of free fatty acid levels in siRBP1 versus control LECs (n = 4). F , G Representative immunostainings of BODIPY-Palmitate 493/503 (green) and ATGL (red) ( F ) and quantification of ATGL intensity ( G ) in the surface of lipid droplets in control versus siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). H–J Representative immunostainings of BODIPY-Palmitate (green) ( H ) and quantification of the number of lipid droplets ( I ) or total lipid droplet area per cell ( J ) in control versus siRBP1 LECs treated with NG-497 (or DMSO as a vehicle control). Nuclei were counterstained with DAPI (n = 3). *P < 0.05 by two-tailed Student’s t-test ( C , G , I , J ) and two-tailed one-sample t-test ( A , D , E ). Scale bars represent 30 µm in B , F , H
    Rabbit Anti Human Atgl Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary/ATGL+Antibody/pmc13756975-310-13-20
    Average 96 stars, based on 1 article reviews
    rabbit anti human atgl primary antibody - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein endothelial cells (HUVECs).

    Journal: Advanced Science

    Article Title: Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

    doi: 10.1002/advs.78697

    Figure Lengend Snippet: The physiochemical characterization of SαV‐DAb. (a) Flow cytometry confirming SIRPα overexpression. (b) Fluorescence imaging validating the SIRPα overexpression (Scale bar = 20 µm). (c) Western blot detecting SIRPα in both parent cells and nanovesicles. GAPDH and Na + /K + ‐ATPase were used as loading references for cell lysates and nanovesicle samples, respectively. (d) Representative transmission electron microscopy (TEM) images of the nanovesicles (Scale bar = 100 nm). (e) Coomassie Brilliant Blue staining demonstrating successful antibody (Ab) conjugation. Arrowheads indicate Ab heavy chains. (f) Simultaneous dual‐Ab modification visualized using fluorescence‐labeled antibodies (scale bar = 20 µm). (g, h) The mean diameter of all types of nanovesicles (g) and the size distribution of SαV‐DAb (h). The size distribution was determined from three batches of prepared SαV‐DAb to reflect intra‐batch and inter‐batch uniformity. Error bars (red) indicate ±1 standard error of the mean (SEM). (i) Zeta potential for SαVs with different antibody modification. (j, k) Stability assessment of SαV and SαV‐DAb incubated in 10% FBS for one week, monitored through changes in diameter (j) and zeta potential (k). (l) Cytotoxicity evaluation of engineered SαV carrying different antibody toward cardiomyoblasts (H9C2) and human umbilical vein endothelial cells (HUVECs).

    Article Snippet: Briefly, rat ventricular cardiomyoblasts (H9C2) and human umbilical vein endothelial cells (HUVECs) were obtained from ATCC.

    Techniques: Flow Cytometry, Over Expression, Fluorescence, Imaging, Western Blot, Transmission Assay, Electron Microscopy, Staining, Conjugation Assay, Modification, Labeling, Zeta Potential Analyzer, Stability, Incubation

    RBP1 silencing induces ATGL-dependent lipid mobilization. A Representative immunoblot of LC3 protein levels in control and siRBP1 LECs (n = 3). Densitometric quantification of protein levels (normalized to GAPDH as loading control and expressed relative to the control condition) is shown beneath the blot. B , C Representative images of BODIPY-palmitate 493/503 (green) staining ( B ) and quantification of lipid droplet density per cell ( C ) in control and siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). D Representative immunoblot of ATG5 protein levels in siRBP1 versus control LECs following treatment with chloroquine (CQ) (n = 3). Densitometric quantification of protein levels (normalized to vinculin as loading control and expressed relative to the control condition) is shown beneath the blot. E LC–MS measurements of free fatty acid levels in siRBP1 versus control LECs (n = 4). F , G Representative immunostainings of BODIPY-Palmitate 493/503 (green) and ATGL (red) ( F ) and quantification of ATGL intensity ( G ) in the surface of lipid droplets in control versus siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). H–J Representative immunostainings of BODIPY-Palmitate (green) ( H ) and quantification of the number of lipid droplets ( I ) or total lipid droplet area per cell ( J ) in control versus siRBP1 LECs treated with NG-497 (or DMSO as a vehicle control). Nuclei were counterstained with DAPI (n = 3). *P < 0.05 by two-tailed Student’s t-test ( C , G , I , J ) and two-tailed one-sample t-test ( A , D , E ). Scale bars represent 30 µm in B , F , H

    Journal: Experimental Hematology & Oncology

    Article Title: RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis

    doi: 10.1186/s40164-026-00842-9

    Figure Lengend Snippet: RBP1 silencing induces ATGL-dependent lipid mobilization. A Representative immunoblot of LC3 protein levels in control and siRBP1 LECs (n = 3). Densitometric quantification of protein levels (normalized to GAPDH as loading control and expressed relative to the control condition) is shown beneath the blot. B , C Representative images of BODIPY-palmitate 493/503 (green) staining ( B ) and quantification of lipid droplet density per cell ( C ) in control and siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). D Representative immunoblot of ATG5 protein levels in siRBP1 versus control LECs following treatment with chloroquine (CQ) (n = 3). Densitometric quantification of protein levels (normalized to vinculin as loading control and expressed relative to the control condition) is shown beneath the blot. E LC–MS measurements of free fatty acid levels in siRBP1 versus control LECs (n = 4). F , G Representative immunostainings of BODIPY-Palmitate 493/503 (green) and ATGL (red) ( F ) and quantification of ATGL intensity ( G ) in the surface of lipid droplets in control versus siRBP1 LECs. Nuclei were counterstained with DAPI (blue) (n = 3). H–J Representative immunostainings of BODIPY-Palmitate (green) ( H ) and quantification of the number of lipid droplets ( I ) or total lipid droplet area per cell ( J ) in control versus siRBP1 LECs treated with NG-497 (or DMSO as a vehicle control). Nuclei were counterstained with DAPI (n = 3). *P < 0.05 by two-tailed Student’s t-test ( C , G , I , J ) and two-tailed one-sample t-test ( A , D , E ). Scale bars represent 30 µm in B , F , H

    Article Snippet: For double ATGL and BODIPY-Palmitate immunostainings, coverslips were permeabilized, blocked and incubated with rabbit anti-human ATGL primary antibody [1:200] (55190-1-AP, Proteintech) overnight at 4 oC.

    Techniques: Western Blot, Control, Staining, Liquid Chromatography with Mass Spectroscopy, Two Tailed Test